department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Tezspire · pharmadog

pharmadog
drugs
Tezspire

drug · antibody

patient view →

tezepelumab

Marketedupdated 2mo ago

by $AMGN AMGEN INC🔗 ChEMBL

Approved

community read0 votes

Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 6 investigational indications.

indications

investigational

Asthma

targets

Thymic stromal lymphopoietin

all catalysts(4)

approval · 4

News(0)

no news has mentioned this drug yet

brand

Tezspire

trade names

Tezspire

generic

tezepelumab-ekko

MOA

Thymic stromal lymphopoietin inhibitor

indication

Eosinophilic Esophagitis

phase

marketed

TEZSPIRE (TEZEPELUMAB-EKKO) — FDA approval

TEZSPIRE (TEZEPELUMAB-EKKO) — FDA approval

TEZSPIRE (TEZEPELUMAB-EKKO) — FDA approval

TEZSPIRE (TEZEPELUMAB-EKKO) — FDA approval

Data sources

openFDA · ClinicalTrials.gov · OpenTargets

last refreshed 30m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

$AZN190.16-2.56%

$AZN190.16-2.56%

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

$AZN190.16-2.56%

$AZN190.16-2.56%

🐶 often sniffed alongside

top 2

tagApproval16 co-mentions · 4 sources
drugTEZSPIRE16 co-mentions · 4 sources

Trials studying tezepelumab

phase3A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthmarecruitingn=231
phase3Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumabrecruitingn=400
phase3Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitisactive not recruitingn=368
phase3A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumabrecruitingn=180
—Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in Italyactive not recruitingn=315
phase3A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)recruitingn=990
phase3A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)recruitingn=990
phase3A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumabnot yet recruitingn=230

more trials →